We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
96 hedge funds and large institutions have $63.2M invested in Lineage Cell Therapeutics in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
67% more call options, than puts
Call options by funds: $20K | Put options by funds: $12K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.34% less ownership
Funds ownership: 43.42% → 43.08% (-0.34%)
10% less funds holding
Funds holding: 107 → 96 (-11)
11% less capital invested
Capital invested by funds: $71.2M → $63.2M (-$8.04M)
22% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 27
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Holders
96
Holders Change
-11
Holders Change %
-10.28%
% of All Funds
2.11%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
10
Increased
21
Reduced
27
Closed
20
Calls
$20K
Puts
$12K
Net Calls
+$8K
Net Calls Change
+$11K
Top Buyers
| 1 |
BlackRock
New York
|
+$205K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$172K |
| 3 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$147K |
| 4 |
State Street
Boston,
Massachusetts
|
+$120K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$75.2K |
